Viridian Therapeutics, Inc. (VRDN)
VRDN moved a median of +0.19% 30 minutes after news, and +0.36% by the close. How VRDN actually reacts to news — the realized, point-in-time move the market made, measured across 277 labeled events over the last three years with zero look-ahead.
VRDN’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.20% | 43% | 277 |
| 30-min | +0.19% | 55% | 277 |
| 60-min | -0.10% | 49% | 277 |
| to close | +0.36% | 52% | 277 |
| Middle 50% of VRDN reactions | -1.78% to +1.40% |
|---|---|
| Median reaction (30-min) | +0.19% |
| Measured reactions | 277 |
Half of all Viridian Therapeutics, Inc. news events land between -1.78% and +1.40% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How VRDN reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 20 | -0.85% | 25% | +0.67% |
| Rating reiterations | 119 | -0.07% | 45% | -0.15% |
| Price-target raises | 18 | +0.63% | 67% | -0.06% |
| Price-target cuts | 25 | -0.31% | 32% | -0.08% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how VRDN ranks against every other measured name →
That’s how VRDN usually reacts — get an email when it moves on news →Email me when VRDN moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to VRDN's baseline. Nothing else.
Recent VRDN events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Viridian Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference | Press release | Business Wire | -1.05% | -0.52% | |
| Form 10-Q Viridian Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +2.05% | +9.64% | |
| Form 8-K Viridian Therapeutics, For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | +2.05% | +9.64% | |
| Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results | Press release | Business Wire | +2.05% | +9.64% | |
| Form 8-K Viridian Therapeutics, For: Jun 26 | SEC filing · Form 8-K | SEC EDGAR | +1.47% | -1.57% | |
| Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease | Press release | Business Wire | +1.47% | -1.57% | |
| Form 8-K Viridian Therapeutics, For: Jun 02 | SEC filing · Form 8-K | SEC EDGAR | +1.65% | +3.55% | |
| Form 8-K Viridian Therapeutics, For: May 27 | SEC filing · Form 8-K | SEC EDGAR | -0.29% | +1.50% | |
| Viridian Therapeutics to Participate in Upcoming June Investor Conferences | Press release | Business Wire | -0.81% | -0.06% | |
| Form 8-K Viridian Therapeutics, For: May 24 | SEC filing · Form 8-K | SEC EDGAR | -0.81% | -0.06% | |
| Form 8-K Viridian Therapeutics, For: May 06 | SEC filing · Form 8-K | SEC EDGAR | -1.07% | -2.09% | |
| Form 305B2 Viridian Therapeutics, | SEC filing · Form 305B2 | SEC EDGAR | -3.19% | -3.19% | |
| Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million | Press release | Business Wire | -3.19% | -3.19% | |
| Form 10-Q Viridian Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +1.51% | +1.41% | |
| Form 8-K Viridian Therapeutics, For: May 05 | SEC filing · Form 8-K | SEC EDGAR | +1.51% | +1.41% | |
| Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL-2 Clinical Trial in Chronic Thyroid Eye Disease | Press release | Business Wire | +1.51% | +1.41% | |
| Viridian Therapeutics Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Stock and Series B Non-Voting Convertible Preferred Stock | Press release | Business Wire | -4.70% | -5.24% | |
| Viridian Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Progress | Press release | Business Wire | +1.51% | +1.41% | |
| Form ARS Viridian Therapeutics, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -0.20% | -0.94% | |
| Form DEF 14A Viridian Therapeutics, For: Jun 02 | SEC filing · Form DEF | SEC EDGAR | -0.20% | -0.94% | |
| Form DEFA14A Viridian Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | -0.20% | -0.94% | |
| Form 8-K Viridian Therapeutics, For: Mar 30 | SEC filing · Form 8-K | SEC EDGAR | +7.76% | +9.00% | |
| Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL-1 Clinical Trial in Active Thyroid Eye Disease | Press release | Business Wire | +7.76% | +9.00% | |
| Form 10-K Viridian Therapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.33% | +9.02% | |
| Form 8-K Viridian Therapeutics, For: Feb 26 | SEC filing · Form 8-K | SEC EDGAR | +0.33% | +9.02% | |
| Form S-8 Viridian Therapeutics, | SEC filing · Form S-8 | SEC EDGAR | +1.69% | +1.27% | |
| Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results | Press release | Business Wire | +0.33% | +9.02% | |
| Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | +0.57% | +2.85% | |
| Viridian Therapeutics Prepares for Transformational 2026 | Press release | Business Wire | +2.49% | +3.47% | |
| Viridian Therapeutics Announces BLA Acceptance and Priority Review for Veligrotug for the Treatment of Thyroid Eye Disease | Press release | Business Wire | +1.12% | +1.03% | |
| Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | +0.29% | -1.29% | |
| Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | -1.53% | -0.04% | |
| Form 10-Q Viridian Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.17% | +4.99% | |
| Form 8-K Viridian Therapeutics, For: Nov 05 | SEC filing · Form 8-K | SEC EDGAR | +0.17% | +4.99% | |
| Viridian Therapeutics Reports Third Quarter 2025 Financial Results and Highlights Recent Progress | Press release | Business Wire | +0.17% | +4.99% | |
| Viridian Therapeutics Announces Successful October Submission of Biologics License Application (BLA) to U.S. FDA for Veligrotug in Thyroid Eye Disease | Press release | Business Wire | +1.23% | -1.49% | |
| Form 8-K Viridian Therapeutics, For: Oct 21 | SEC filing · Form 8-K | SEC EDGAR | +0.16% | +0.78% | |
| Form 8-K Viridian Therapeutics, For: Oct 21 | SEC filing · Form 8-K | SEC EDGAR | -1.30% | -8.06% | |
| Viridian Therapeutics Announces Pricing of $251 Million Public Offering of Shares of Common Stock | Press release | Business Wire | -1.30% | -8.06% | |
| Viridian Therapeutics Announces Proposed Underwritten Public Offering | Press release | Business Wire | -1.30% | -8.06% | |
| Form 8-K Viridian Therapeutics, For: Oct 17 | SEC filing · Form 8-K | SEC EDGAR | +0.61% | -1.79% | |
| Viridian Therapeutics Announces Royalty Financing with DRI Healthcare for up to $300 Million | Press release | Business Wire | +0.61% | -1.79% | |
| Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | +0.60% | +1.93% | |
| Viridian Therapeutics Announces Completion of Enrollment in both REVEAL Clinical Trials and Positive Portfolio Updates | Press release | Business Wire | -0.48% | -4.56% | |
| Form S-3ASR Viridian Therapeutics, | SEC filing · Form S-3ASR | SEC EDGAR | +0.40% | +0.65% | |
| Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | +0.67% | -3.77% | |
| Form 10-Q Viridian Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -2.17% | -3.04% | |
| Form 8-K Viridian Therapeutics, For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | -2.17% | -3.04% | |
| Form S-8 Viridian Therapeutics, | SEC filing · Form S-8 | SEC EDGAR | -1.13% | -4.01% | |
| Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2025 Financial Results | Press release | Business Wire | -2.17% | -3.04% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the VRDN section they belong to.
Where else VRDN is measured.
VRDN earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Viridian Therapeutics, Inc.'s median reaction calculated?
Every labeled VRDN news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 277 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 55% of VRDN's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does VRDN's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.